Literature DB >> 14654912

Role of surgery in local treatment of Ewing's sarcoma of the extremities in patients undergoing adjuvant and neoadjuvant chemotherapy.

Gaetano Bacci1, Stefano Ferrari, Alessandra Longhi, Davide Donati, Enza Barbieri, Cristiana Forni, Franco Bertoni, Marco Manfrini, Stefano Giacomini, Patrizia Bacchini.   

Abstract

Although more and more patients with Ewing's sarcoma of bone (ESB) are being treated by surgery, the relative role of surgery and radiotherapy in the local treatment of this tumor has yet to be determined. Because the outcome of ESB may differ according to the anatomical site of the tumor, results reported in the literature, which generally refer to series with tumors located in all sites, may be selection biased. Therefore, we have retrospectively evaluated patients with ESB exclusively in the extremity and locally treated by surgery or radiotherapy. Two hundred and sixty-eight patients treated at Rizzoli 1979-1996 for non-metastatic ES of the extremities were assessed. Chemotherapy was administered according to four sequentially activated protocols. One hundred and thirty-six patients were treated by surgery, 70 by surgery and radiotherapy, and 60 patients by radiotherapy. Two patients underwent only chemotherapy. The follow-up range was 5-23 years (mean 13 years). One hundred and fifty-two patients remained continuously free of disease, 108 relapsed, 2 died of chemotherapy toxicity and 6 developed a second malignancy. The 5-year event-free survival (EFS) and overall survival (OS) were respectively 62 and 69%. Although patients of all groups were matched for possible risk factors, the rates of 5-year EFS and local control were significantly lower in patients treated with radiotherapy compared to patients treated by surgery or surgery and radiotherapy (48% vs 66%, p=0.002; 80% vs 94%, p=0.0001). Furthermore, in group 3 there were 6 secondary malignancies. Our results indicate that surgery should always be considered in the local treatment of ES of the extremities. Postoperative radiation therapy must be added in case of inadequate surgical margins.

Entities:  

Mesh:

Year:  2004        PMID: 14654912

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  Long-lasting multiagent chemotherapy in adult high-risk Ewing's sarcoma of bone.

Authors:  Selmin Ataergin; Ahmet Ozet; Luis Solchaga; Mustafa Turan; Murat Beyzadeoglu; Kaan Oysul; Fikret Arpaci; Seref Komurcu; Serdar Surenkok; Mustafa Ozturk
Journal:  Med Oncol       Date:  2008-11-07       Impact factor: 3.064

2.  Results of RS-99 protocol for childhood solid tumors.

Authors:  Jiao-Yang Cai; Jing-Yan Tang; Ci Pan; Min Xu; Hui-Liang Xue; Min Zhou; Lu Dong; Qi-Dong Ye; Hua Jiang; Shu-Hong Shen; Jing Chen
Journal:  World J Pediatr       Date:  2010-02-09       Impact factor: 2.764

3.  Extracorporeal irradiated tumor bone: A reconstruction option in diaphyseal Ewing's sarcomas.

Authors:  Ajay Puri; Ashish Gulia; Mg Agarwal; Na Jambhekar; S Laskar
Journal:  Indian J Orthop       Date:  2010-10       Impact factor: 1.251

Review 4.  Bone tumors in adolescents and young adults.

Authors:  Stefan S Bielack; Dorothe Carrle; Jendrik Hardes; Andreas Schuck; Michael Paulussen
Journal:  Curr Treat Options Oncol       Date:  2008-05-01

5.  Ewing family tumors of the appendicular skeleton: a retrospective analysis of prognostic factors.

Authors:  Francesco Muratori; Lorenzo Foschi; Giuliana Roselli; Filippo Frenos; Angela Tamburini; Annarita Palomba; Daniela Greto; Mauro Loi; Giovanni Beltrami; Rodolfo Capanna; Nicola Mondanelli; Domenico Andrea Campanacci
Journal:  Eur J Orthop Surg Traumatol       Date:  2021-07-29

6.  A nomogram to predict prognosis in Ewing sarcoma of bone.

Authors:  Qiang Zhou; Zong-Yi Wu; Zhong-Qin Lin
Journal:  J Bone Oncol       Date:  2019-02-12       Impact factor: 4.072

7.  Easy-to-use clinical tool for survival estimation in Ewing sarcoma at diagnosis and after surgery.

Authors:  S E Bosma; C Lancia; A J Rueten-Budde; A Ranft; H Gelderblom; M Fiocco; M A J van de Sande; P D S Dijkstra; U Dirksen
Journal:  Sci Rep       Date:  2019-07-29       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.